Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.
Linong JiYing DuMin XuXiangjun ZhouZhaohui MoJian-Hua MaJiarui LiYufeng LiJingna LinYan-Jun WangJing YangWeihong SongHui JinShuguang PangHui LiuPing LiJie LiuMinxiu YaoWenhui LiXiaohong JiangFeixia ShenHoufa GengHaifeng ZhouJianmin RanMinxiang LeiYinghong DuShandong YeQingbo GuanWenshan LvHuiwen TanTao ChenJinkui YangGuijun QinShiyun LiLei ChenPublished in: Diabetologia (2021)
ClinicalTrials.gov NCT03520972 FUNDING: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio.
Keyphrases
- double blind
- phase ii
- clinical trial
- placebo controlled
- open label
- end stage renal disease
- quality improvement
- phase iii
- ejection fraction
- study protocol
- newly diagnosed
- peritoneal dialysis
- cardiovascular disease
- prognostic factors
- randomized controlled trial
- hiv infected
- type diabetes
- patient reported outcomes
- adipose tissue
- patient reported
- insulin resistance
- drug induced
- weight loss
- antiretroviral therapy